| Michael Christopher Eddins, MD | |
|
250 State Farm Pkwy, Birmingham, AL 35209 | |
| (205) 943-4650 | |
| Not Available |
| Full Name | Michael Christopher Eddins |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 10 Years |
| Location | 250 State Farm Pkwy, Birmingham, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487065868 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | MD.36744 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eye Health Partners Of Alabama Inc | 4385530740 | 15 |
News Archive
Healthcare professionals are one of the most vulnerable groups exposed to infections. Rising number of coronavirus cases and severe shortage of personal protective equipment products across India are putting them at more risk.
Conventional wisdom holds that the more people stay within their own social groups and avoid others, the less likely a small disease outbreak will turn into full-blown epidemic. But this conventional wisdom might be quite wrong, according to two Santa Fe Institute researchers, and the consequences could reach far beyond epidemiology.
Any benefit of dual blockade of the renin angiotensin system is limited to its effects on surrogate endpoints, and outweighed by an excessive risk for adverse events such as hypotension, hyperkalemia, and renal failure, argue hypertension experts.
Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that on September 4, 2009 it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (the "Staff") notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing, set forth in Listing Rule 5550(b), prior to the expiration of the extension for such compliance granted by the Staff on June 25, 2009, and that as a result, unless the Company requests an appeal of the Staff's delisting determination, trading of the Company's common stock on the Nasdaq Capital Market will be suspended at the opening of business on September 15, 2009.
› Verified 1 days ago
| Entity Name | Eye Health Partners Of Alabama Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619923745 PECOS PAC ID: 4385530740 Enrollment ID: O20040227000240 |
News Archive
Healthcare professionals are one of the most vulnerable groups exposed to infections. Rising number of coronavirus cases and severe shortage of personal protective equipment products across India are putting them at more risk.
Conventional wisdom holds that the more people stay within their own social groups and avoid others, the less likely a small disease outbreak will turn into full-blown epidemic. But this conventional wisdom might be quite wrong, according to two Santa Fe Institute researchers, and the consequences could reach far beyond epidemiology.
Any benefit of dual blockade of the renin angiotensin system is limited to its effects on surrogate endpoints, and outweighed by an excessive risk for adverse events such as hypotension, hyperkalemia, and renal failure, argue hypertension experts.
Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that on September 4, 2009 it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (the "Staff") notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing, set forth in Listing Rule 5550(b), prior to the expiration of the extension for such compliance granted by the Staff on June 25, 2009, and that as a result, unless the Company requests an appeal of the Staff's delisting determination, trading of the Company's common stock on the Nasdaq Capital Market will be suspended at the opening of business on September 15, 2009.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Christopher Eddins, MD 250 State Farm Pkwy, Birmingham, AL 35209-7181 Ph: (205) 943-4650 | Michael Christopher Eddins, MD 250 State Farm Pkwy, Birmingham, AL 35209 Ph: (205) 943-4650 |
News Archive
Healthcare professionals are one of the most vulnerable groups exposed to infections. Rising number of coronavirus cases and severe shortage of personal protective equipment products across India are putting them at more risk.
Conventional wisdom holds that the more people stay within their own social groups and avoid others, the less likely a small disease outbreak will turn into full-blown epidemic. But this conventional wisdom might be quite wrong, according to two Santa Fe Institute researchers, and the consequences could reach far beyond epidemiology.
Any benefit of dual blockade of the renin angiotensin system is limited to its effects on surrogate endpoints, and outweighed by an excessive risk for adverse events such as hypotension, hyperkalemia, and renal failure, argue hypertension experts.
Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that on September 4, 2009 it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (the "Staff") notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing, set forth in Listing Rule 5550(b), prior to the expiration of the extension for such compliance granted by the Staff on June 25, 2009, and that as a result, unless the Company requests an appeal of the Staff's delisting determination, trading of the Company's common stock on the Nasdaq Capital Market will be suspended at the opening of business on September 15, 2009.
› Verified 1 days ago
Carol E Rosenstiel, OD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 700 18th St S Ste 200, Birmingham, AL 35233 Phone: 205-325-8620 | |
Alex J Wright, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 1720 University Blvd, Birmingham, AL 35233 Phone: 205-325-8100 Fax: 205-325-8547 | |
Elmar M Lawaczeck, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1009 Montgomery Hwy, Suite 200, Birmingham, AL 35216 Phone: 205-397-9400 Fax: 205-397-9455 | |
Matthew Henry Oltmanns, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2208 University Blvd Ste 101, Birmingham, AL 35233 Phone: 205-933-2625 Fax: 205-558-2553 | |
Harold Augustus Helms, MD, PHD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1100 23rd St S, Ste 100, Birmingham, AL 35205 Phone: 205-933-2020 Fax: 205-933-0908 | |
Krupa Hasmukh Patel, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 700 18th St S Ste 601, Birmingham, AL 35233 Phone: 205-325-8620 | |
William Charles Gambla, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 700 18th St S Ste 601, Birmingham, AL 35233 Phone: 205-996-8660 |